JADEClinical Trials•globenewswire•
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Sentiment:Positive (70)
Summary
(JADE) First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by globenewswire